B7-H3 Targeted Therapies Market Key Trends and Future Outlook
https://researchintelo.com/rep....ort/b7-h3-targeted-t
According to our latest research, the B7-H3 Targeted Therapies market size was valued at $1.2 billion in 2024 and is projected to reach $7.8 billion by 2033, expanding at a robust CAGR of 23.5% during the forecast period of 2025–2033. The primary driver fueling the global B7-H3 Targeted Therapies market is the increasing prevalence of treatment-resistant cancers and the urgent need for more selective, less toxic therapeutic options. B7-H3, an immune checkpoint molecule, has emerged as a compelling target for next-generation immunotherapies due to its overexpression in various malignancies and its role in tumor immune evasion. This scientific advancement, combined with the rapid evolution of antibody engineering and cellular therapies, is propelling the adoption and development of B7-H3 targeted modalities across oncology pipelines worldwide.
